Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Diabetes Mellitus, Type 2 · Pharmacokinetic trial

Boehringer Ingelheim

Boehringer Ingelheim clinical programs — 31 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE HQ
46,699 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE
Employees
46,699
Programs
193
Drugs
113
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Boehringer Ingelheim projects

31 ClinicalTrials.gov programs sponsored by Boehringer Ingelheim.

Boehringer Ingelheim has 31 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

31 programs

Clinical programs

  1. 1366-0055

    Boehringer Ingelheim

    clinically significant portal hypertension (CSPH) in decompensated cirrhosis due to non-cholestatic liver disease

    phase 2 small molecule active

    1 trial

  2. 1378-0023

    Boehringer Ingelheim

    chronic kidney disease

    phase 2 small molecule active

    1 trial

  3. 1403-0032

    Boehringer Ingelheim

    Solid tumours

    phase 2 small molecule active

    1 trial

  4. 1425-0003

    Boehringer Ingelheim

    Crohn`s Disease (CD)

    phase 2 small molecule active

    1 trial

  5. 1434-0004

    Boehringer Ingelheim

    Focal segmental glomerulosclerosis

    phase 2 small molecule active

    1 trial

  6. 1447-0005

    Boehringer Ingelheim

    Major depressive disorder

    phase 2 other active

    1 trial

  7. 1462-0004

    Boehringer Ingelheim

    idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  8. 1479-0012

    Boehringer Ingelheim

    gastroesophageal junction adenocarcinoma, metastatic gastric adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, esophageal adenocarcinoma

    phase 2 small molecule active

    1 trial

  9. 1479-0044

    Boehringer Ingelheim

    locally advanced or metastatic NSCLC

    phase 2 small molecule active

    1 trial

  10. 1485-0018

    Boehringer Ingelheim

    Centre-involved diabetic macular edema

    phase 2 small molecule active

    1 trial

  11. 1490-0004

    Boehringer Ingelheim

    Progressive pulmonary fibrosis (PPF), Idiopathic pulmonary fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  12. 1504-0001

    Boehringer Ingelheim

    Cystic fibrosis

    phase 2 small molecule active

    1 trial

  13. 1509-0004

    Boehringer Ingelheim

    Systemic lupus erythematosus

    phase 2 small molecule active

    1 trial

  14. Afatinib once daily (OD)

    Boehringer Ingelheim

    Breast Neoplasms

    phase 2 small molecule completed

    1 trial

  15. Avenciguat

    Boehringer Ingelheim

    Chronic Kidney Disease

    phase 2 small molecule completed

    1 trial

  16. BI 1744 CL 2 µg

    Boehringer Ingelheim

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  17. BI 1810631

    Boehringer Ingelheim

    HER2-mutated or overexpressed/amplified solid tumours

    phase 2 small molecule active

    1 trial

  18. BI 3720931, BI 3720931

    Boehringer Ingelheim

    Cystic fibrosis

    phase 2 small molecule active

    1 trial

  19. BI 456906

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  20. BI 655130

    Boehringer Ingelheim

    Dermatitis, Atopic

    phase 2 small molecule completed

    1 trial

  21. BI 671800

    Boehringer Ingelheim

    Asthma

    phase 2 small molecule completed

    1 trial

  22. BI 764198

    Boehringer Ingelheim

    Proteinuric Kidney Diseases

    phase 2 small molecule active

    1 trial

  23. BI 764524, Sham Injection Procedure

    Boehringer Ingelheim

    Diabetic retinopathy

    phase 2 small molecule active

    1 trial

  24. Placebo matching BI 764198, BI 764198

    Boehringer Ingelheim

    Proteinuric kidney diseases

    phase 2 small molecule active

    1 trial

  25. Placebo to BI 765423, BI 765423

    Boehringer Ingelheim

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  26. Spesolimab

    Boehringer Ingelheim

    Generalized Pustular Psoriasis

    phase 2 small molecule active

    1 trial

  27. Tipranavir

    Boehringer Ingelheim

    HIV Infections

    phase 2 small molecule completed

    1 trial

  28. Vicadrostat

    Boehringer Ingelheim

    Chronic Kidney Disease

    phase 2 small molecule active

    1 trial

  29. linagliptin low dose

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  30. ribavirin (RBV)

    Boehringer Ingelheim

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  31. tiotropium-bromide

    Boehringer Ingelheim

    Asthma

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Boehringer Ingelheim have?

31 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.